Shuichiro Matoba

Prof. Shuichiro Matoba

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 August 2025 in Clinical Cancer Research
Verified
Journal Article
Closed access
TATakashi Akiyoshi
Takashi Akiyoshi
ESEiji Shinozaki
Eiji Shinozaki
YMYusuke Maeda
Yusuke Maeda
STSenzo Taguchi
Senzo Taguchi
ACAkiko Chino
Akiko Chino
KYKensei Yamaguchi
Kensei Yamaguchi
Purpose: The role of ctDNA in total neoadjuvant therapy (TNT) and nonoperative management (NOM) for locally advanced rectal cancer (LARC) remains unclear. We evaluated the association of ctDNA with clinical outcomes, including treatment response, local regrowth, and distant recurrence in patients undergoing TNT and NOM. Experimental Design: This biomarker companion analysis of the NOMINATE trial, a prospective, multicenter, randomized phase II study, enrolled 64 patients with T3 to T4NanyM0 LARC between March 2021 and July 2023. Plasma samples (n = 412) were collected at multiple time points: pretreatment (T0), interim evaluations (T1 and T2), final re-staging (T3), and after surgery or after NOM (T4 and beyond). ctDNA was monitored using a tumor-informed multiplex polymerase chain reaction–next generation sequencing assay (Signatera). The association between ctDNA status and clinical outcomes was analyzed. Results: Baseline ctDNA detection was 98.4%, which decreased to 32% at T1, 15% at T2, 30% at T3, and 5% at T4. Among 25 patients achieving clinical complete response (cCR) or near cCR with NOM, ctDNA clearance was 100% at T2 to T4, whereas 39 non-cCR patients showed lower clearance rates (75% at T2 and 51% at T3). ctDNA at T3 had 100% specificity and positive predictive value for pathologic residual disease and was associated with shorter disease-free survival (HR = 6.7, P = 0.005). Local regrowth occurred in five NOM patients, with ctDNA detected in two during surveillance. Conclusions: This study highlights the potential of ctDNA as a predictive and prognostic biomarker in patients with LARC undergoing TNT and subsequently managed by NOM. However, the modest sensitivity of ctDNA highlights the need for technological improvements. See related commentary by Bent et al., p. 5117

3 February 2022 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
YFYudai Fukui
Yudai Fukui
KHKoy Hid
Koy Hid
NHNobuaki Hoshino
Nobuaki Hoshino
SSSeung Ho Song
Seung Ho Song
SPSoo Yeun Park
Soo Yeun Park
YSYoshiharu Sakai
Yoshiharu Sakai

30 March 2026 in Journal of Robotic Surgery
Verified
Journal Article
Open access
PDF file
STShigeo Toda
Shigeo Toda
KHKosuke Hiramatsu
Kosuke Hiramatsu
SMShuichiro Matoba
Shuichiro Matoba
YMYusuke Maeda
Yusuke Maeda
NONaoto Okazaki
Naoto Okazaki
HKHiroya Kuroyanagi
Hiroya Kuroyanagi
The Hugo RAS system (Hugo), comprising an open surgical console and independent arm carts was launched into the surgical robotics market following the da Vinci surgical system (da Vinci). This study was designed to disclose the feasibility of rectal surgery using Hugo vs. da Vinci systems by assessing short-term outcomes. Between September 2019 and October 2025, 211 patients underwent robotic surgery for non-metastatic rectal cancer. The outcomes of 81 Hugo-assisted and 130 da Vinci-assisted robotic surgeries were compared. The incidence of postoperative complications classified as Clavien–Dindo (CD) grade III or higher was the primary outcome. Secondary outcomes were blood loss, operative time, console time, positive circumferential resection margin (CRM), postoperative hospital stay, and mortality. Hugo and da Vinci cases were compared using 1:1 propensity score matching, balancing for age, sex, BMI, ASA-PS, tumor location, clinical T and N stage, preoperative therapy, surgeon experience, console experience and sphincter preservation. After matching, each group included 56 patients with comparable pretreatment characteristics. There were no significant differences between the Hugo and da Vinci groups in CD grade ≥ III complications (7.1% vs. 8.9%, p = 1.000), blood loss, operative time, console time, CRM positivity, postoperative hospital stay, or mortality. No open conversions occurred in either group. The Hugo system enables feasible rectal surgery with no significant differences in short-term outcomes compared with those achieved using the da Vinci system.

1 January 2012 in Nihon Daicho Komonbyo Gakkai Zasshi
Verified
Journal Article
Open access
PDF file
YHYutaka Hanaoka
Yutaka Hanaoka
SMShuichiro Matoba
Shuichiro Matoba
STShigeo Toda
Shigeo Toda
JMJin Moriyama
Jin Moriyama
HKHiroya Kuroyanagi
Hiroya Kuroyanagi
TSToshihito Sawada
Toshihito Sawada

11 October 2016 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
MNM. Noda
M. Noda
TSTakeo Sato
Takeo Sato
KHK. Hayakawa
K. Hayakawa
NTN. Tomita
N. Tomita
NKN. Kamikonnya
N. Kamikonnya
MWM. Watanabe
M. Watanabe
Background: We previously conducted a phase I study of preoperative concurrent chemoradiotherapy combining S-1 and irinotecan with radiotherapy of the lesser pelvis in patients with resectable, locally advanced rectal cancer (SAMRAI-1 Trial). The maximum tolerated dose (MTD) of irinotecan was 80 mg/m2, and the recommended dose was 60 mg/m2. We thus conducted a phase II study (SAMRAI-2 Trial) to further evaluate efficacy and safety.

20 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SKShigehiro Koganemaru
Shigehiro Koganemaru
NINaoko Inoshita
Naoko Inoshita
YMYuji Miura
Yuji Miura
YFYudai Fukui
Yudai Fukui
YOYukinori Ozaki
Yukinori Ozaki
TTToshimi Takano
Toshimi Takano
3568 Background: The programmed death-1 (PD-1)/PD-L1 pathway is a negative feedback mechanism that suppresses the activity of T cells. PD-L1 was expressed on tumor cells (TCs) or tumor-infiltrating immune cells (ICs) in several malignancies. We previously reported that high PD-L1 expression on TCs and ICs were associated with poor and better prognosis in patients with stage IIIb colorectal cancer, respectively. We reported whether these findings were validated in patients with stage III colorectal cancer. Methods: Formalin-fixed paraffin-embedded (FFPE) blocks specimens were obtained from the patients with stage III colorectal cancer who underwent surgical resection and adjuvant chemotherapy at our institution between January 2009 and July 2012. We excluded patients who received radiotherapy or chemoradiotherapy before surgery. PD-L1 expression was evaluated by immunohistochemistry (IHC) on TCs and ICs. Specimens were scored as IHC low (L) or high (H), when < 5% or ≥ 5% of cells were PD-L1 positive, respectively. Results: Two hundred and thirty-five patients were included in this analysis. Median age was 63 years (range 32-84). One hundred and seventy-four and 61 patients received fluoropyrimidine and fluoropyrimidine combined with oxaliplatin as adjuvant chemotherapy, respectively. The number of patients with PD-L1 expression on TCs/ICs (H/H, H/L, L/H, and L/L) was 0, 19, 36, and 180, respectively. The median follow-up time of this study was 52.9 months. Patients with high PD-L1 expression on TCs had significantly shorter disease-free survival (DFS) than patients with low expression (hazard ratio [HR] 2.36; 95% confidence interval [CI], 1.21-4.62; p = 0.012). Meanwhile, patients with high PD-L1 expression on ICs were associated with longer DFS than patients with low expression (HR 0.40; 95% CI, 0.16-0.98; p = 0.046). Conclusions: High PD-L1 expression on TCs negatively affect the survival, whereas high PD-L1 expression on ICs is associated with favorable prognosis of patients with stage III colorectal cancer.